Differences in EGFR and KRAS mutation spectra in lung adenocarcinoma of never and heavy smokers

Oncology Letters

Volumn 6, Issue 5, 2013, Pages 1207-1212

  Takamochi, Kazuya ^a   Oh, Shiaki ^a   Suzuki, Kenji ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adenocarcinoma; Epidermal growth factor receptor; KRAS; Lung cancer; Mutation; Smoking

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN;

ADULT; AGED; ARTICLE; FEMALE; GENE MUTATION; GENE STRUCTURE; GENOTYPE; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; SMOKING; TUMOR VOLUME;

EID: 84884497163     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1551     Document Type: Article

References (28)

1. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346, 2005.
2. Rodenhuis S, van de Wetering ML, Mooi WJ, EversSG, van ZandwijkN and Bos JL: Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 317: 929-935, 1987.
3. Chan SK, Gullick WJ and Hill ME: Mutations of the epidermal growth factor receptor in non-small cell lung cancer-search and destroy. Eur J Cancer 42: 17-23, 2006.
4. Ahrendt SA, Decker PA, Alawi EA, et al: Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 92: 1525-1530, 2001.
5. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med350: 2129-2139, 2004.
6. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science304: 1497-1500, 2004.
7. Pham D, Kris MG, Riely GJ, et al: Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 24: 1700-1704, 2006.
8. Sugio K, Uramoto H, Ono K, et al: Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer 94: 896-903, 2006.
9. Pao W, Wang TY, Riely GJ, et al: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2: e17, 2005.
10. Bos JL: Ras oncogenes in human cancer: a review. Cancer Res49: 4682-4689, 1989.
11. Miller VA, Riely GJ, Zakowski MF, et al: Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 26: 1472-1478, 2008.
12. Nagai Y, Miyazawa H, Huqun, et al: Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res65: 7276-7282, 2005.
13. Thiede C, Bayerdörffer E, Blasczyk R, Wittig B and NeubauerA: Simple and sensitive detection of mutations in the ras proto-oncogenes using PNA-mediated PCR clamping. Nucleic Acids Res 24: 983-984, 1996.
14. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and ParkinDM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
15. Toh CK, Gao F, Lim WT, et al: Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol24: 2245-2251, 2006.
16. Chen YR, Fu YN, Lin CH, et al: Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. Oncogene 25: 1205-1215, 2006.
17. Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY and YangPC: Effectiveness of tyrosine kinase inhibitors on 'uncommon' epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res17: 3812-3821, 2011.
18. De Pas T, Toffalorio F, Manzotti M, et al: Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations. J Thorac Oncol6: 1895-1901, 2011.
19. Bennett WP, Hussain SP, Vahakangas KH, Khan MA, ShieldsPG and Harris CC: Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. J Pathol 187: 8-18, 1999.
20. Le Calvez F, Mukeria A, Hunt JD, et al: TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res65: 5076-5083, 2005.
21. Riely GJ, Kris MG, Rosenbaum D, et al: Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 14: 5731-5734, 2008.
22. Allegra CJ, Jessup JM, Somerfield MR, et al: American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol27: 2091-2096, 2009.
23. O'Byrne KJ, Gatzemeier U, Bondarenko I, et al: Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol12: 795-805, 2011.
24. Pirker R, Pereira JR, Szczesna A, et al: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet373: 1525-1531, 2009.
25. Mollerup S, Jorgensen K, Berge G and Haugen A: Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer 37: 153-159, 2002.
26. Stabile LP, Davis AL, Gubish CT, et al: Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 62: 2141-2150, 2002.
27. Yu IT, Chiu YL, Au JS, Wong TW and Tang JL: Dose-response relationship between cooking fumes exposures and lung cancer among Chinese nonsmoking women. Cancer Res 66: 4961-4967, 2006.
28. Kleinerman RA, Wang Z, Wang L, et al: Lung cancer and indoor exposure to coal and biomass in rural China. J Occup Environ Med 44: 338-344, 2002.